ResearcherShanghai Jiao Tong UniversityNo recent work listed

Feiyang Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1457-0077; OpenAlex author ID A5101936350. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2021: 2 papers

Papers 2

Dyslipidemia in Chinese Pancreatic Cancer Patients: A Two-Center Retrospective Study. Co-author DOI 10.7150/jca.60340 ↗
Decreased NSG3 enhances PD-L1 expression by Erk1/2 pathway to promote pancreatic cancer progress. Co-author PMID 33791163 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Li Huang · 1 shared paper, 2021 · strength 0.16
- Paper Dyslipidemia in Chinese Pancreatic Cancer Patients: A Two-Center Retrospective Study. DOI 10.7150/jca.60340 ↗
Junming Xu · 1 shared paper, 2021 · strength 0.16
- Paper Dyslipidemia in Chinese Pancreatic Cancer Patients: A Two-Center Retrospective Study. DOI 10.7150/jca.60340 ↗
Heshui Wu · 1 shared paper, 2021 · strength 0.16
- Paper Dyslipidemia in Chinese Pancreatic Cancer Patients: A Two-Center Retrospective Study. DOI 10.7150/jca.60340 ↗
Xigang Xia · 1 shared paper, 2021 · strength 0.14
- Paper Decreased NSG3 enhances PD-L1 expression by Erk1/2 pathway to promote pancreatic cancer progress. PMID 33791163 ↗
Rui Wang · 1 shared paper, 2021 · strength 0.14
- Paper Decreased NSG3 enhances PD-L1 expression by Erk1/2 pathway to promote pancreatic cancer progress. PMID 33791163 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.